2021-07-25 01:14:09 UTC
the Delta variant has a 137% higher risk of death
July 24, 2021 by archyde
The World Health Organization (WHO) confirmed a greater danger of the
Delta variant of the coronavirus than increases the risk of death by
The data are based on studies conducted in Canada and China that have
not been published in scientific journals at this time.
According to the Canadian study, the health risks of contracting
COVID-19 with the Delta variant, the danger of having to go to the
hospital increases by around 120 percent, and that of needing intensive
care is around 287 percent, so the risk of death rises to 137 percent.
For the China study, people who were quarantined after contact with
someone infected with the Delta variant were examined, those who were
tested positive for the PCR test after an average of four days, instead
of six, as was the case with the first variants.
Likewise, the viral load was found to be 1,200 times higher in the first
positive test than in the original variants of the virus.
The result of those works It suggests that this worrying variant may
reproduce more quickly and be more contagious in the early stages of
infection., reported the WHO.
The organization also pointed out that the Delta variant already
accounts for more than three-quarters of new COVID cases in many
countries and will predominate in the coming months.
It (the Delta variant) is expected to quickly supplant the other
variants and become the dominant lineage in circulation in the coming
monthssaid the UN agency.
The Delta variant, which was first detected in India and now has a
presence in 124 countries and territories, 13 more than last week,
compared to 180 (six more) for the Alpha variant, which was detected in
the United Kingdom. , the 130 (seven more) of the Beta, which was
identified for the first time in South Africa, and the 78 (three more)
of the Gamma, which appeared in Brazil.
Global alarm: Delta variant has 137% higher risk of death.
Why is the Delta variant so contagious?
With the aim of answering this question, a group of Chinese researchers
from the local Centers for Disease Control and Prevention in Guandong
set the goal of knowing the spread and infection times of the Delta
The results, which were published in the journal Virological, indicate
that the incubation and subsequent positive patient indicator after the
PCR sample is at least two days less than the original strain of
In this way, the amount of time the virus needed to replicate at high
enough levels as to be detectable it was 5.61 days for the original
virus and 3.71 days for the Delta variant.
John Connor, a researcher at the National Laboratories for Emerging
Infectious Diseases at Boston University, told LiveScience that this
indicates that the contagion window is much smaller, which increases the
spread more quickly.
As we know, individuals experience a latent period after infection,
during which viral titers (concentrations) are too low to be detected.
As viral proliferation continues within the host, the viral load will
eventually reach a detectable level. and it will become infectious.
Knowing when an infected person can spread viruses is essential to
design intervention strategies to break the chains of transmission,
said the expert.
The Chinese researchers found that the viral loads in the delta variant
infections were 1,260 times higher than those of the original virus
infections. This suggests that the Delta variant can replicate in the
body at a faster rate than the parent virus.
Research data from Canada has shown that one dose of the Covid-19
vaccine from AstraZeneca and the University of Oxford is 82 percent
effective against hospitalization or death caused by Beta / Gamma
variants of the virus. SARS-CoV-2, as well as 87 percent versus Delta
and 90 percent versus Alpha.
Based on these results, the vaccine was effective against milder
symptomatic disease although, as data were only reported after a first
dose rather than the indicated two-dose schedule, where efficacy is
known to be higher in this setting of disease, the efficacy was lower
than against severe disease. The efficacy of the vaccine against any
A phase I / II trial carried out by the University of Oxford and the
University of the Witwatersrand in January had shown limited efficacy
against mild disease mainly due to the Beta variant. It was unable to
adequately determine the efficacy of the vaccine against severe illness,
including hospitalization and death, as the subjects were predominantly
healthy young adults who only experienced mild illness.
With different variants that threaten to disrupt our exit route from
the pandemic, this real-world evidence shows that our vaccine provides a
high level of protection against the most severe forms of the disease,
even after a single injection. It is essential that Lets continue to
protect as many people as possible in every corner of the world to stay
ahead of this deadly virus, AstraZeneca Executive Vice President of
Biopharmaceutical R&D, Mene Pangalos, told Infosalus.
The analysis included 69,533 individuals who tested positive for
SARS-CoV-2 during December 2020 to May 2021 in Ontario, Canada; with
28,705 (6.8 percent) positive for non-worrisome variants of SARS-CoV-2
and 40,828 (9.7 percent) positive for a worrying variant.